|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cyclacel And ALTANA Pharma AG (AAA) Announce Collaboration On Mitotic Target Identification
10/19/2005 5:13:01 PM
DUNDEE, Scotland & KONSTANZ, Germany--(BUSINESS WIRE)--March 16, 2005--Cyclacel Group plc ("Cyclacel"), the cell cycle-based biopharmaceutical company, announced today execution of a research collaboration agreement with ALTANA Pharma AG, the pharmaceutical division of ALTANA AG (NYSE:AAA)(FWB:ALT), in which Cyclacel will use its expertise in mitosis or cell division to identify the molecular targets of specific ALTANA Pharma experimental drugs.
Under the terms of the agreement ALTANA Pharma will supply Cyclacel with selected experimental molecules shown to interfere with mitosis. Scientists at Cyclacel's Polgen Division in Cambridge, UK, where the work will be undertaken, will apply their knowledge of mitosis biology combined with Cyclacel's Drosophila RNA interference library to identify the targets of the ALTANA Pharma molecules. Knowledge of the drug targets will enable ALTANA Pharma to accelerate the development of drug candidates. Financial terms of the agreement were not disclosed.
|
|
|
|
|
|
|
|
|
|
|